After 3 years of continuous enrollment due to the pandemic, those on Medicaid will need to sign up again for coverage in April; fears about heavy metal levels in baby food prompt FDA to decrease lead exposure; long COVID is keeping large numbers of people out of work or needing medical care after returning.
Read More
Eli Lilly will tack on $450 million more to increase capacity in a diabetes drug plant in light of shortages; patients emailing and messaging medical providers online might be charged; 57% of adults in a recent survey think that the federal government should secure health care coverage for all Americans.
Read More
An Overview of the Treatment Landscape for Patients With Atopic Dermatitis: Dr Jerry Bagel
January 20th 2023Despite a recent influx of new treatments, it is crucial to remind patients there is no cure for atopic dermatitis and follow-up care is important, explained Jerry Bagel, MD, director of the Eczema Treatment Center of New Jersey.
Read More
What We’re Reading: US Hits Debt Limit; More Oversight of Organics; Drug-Resistant Gonorrhea
January 20th 2023As the country hits the debt limit spending on Medicare and Medicaid may be at risk; the Agriculture Department targets fraudulent claims in products labeled as organic; first cases of drug-resistant gonorrhea strain found.
Read More
The reality of a sickle cell disease cure brings fear, optimism, and questions to patients’ lives; veterans who are in suicidal crisis can receive free emergency care at any Department of Veterans Affairs or private facility; Pfizer to increase access to progressive treatments through sale of drugs at non-profit prices to poor countries.
Read More
Endometriosis Is Common, but Challenging to Diagnose and Treat: Dr Ayman Al-Hendy
January 13th 2023Endometriosis is a very common disease across ethnic groups and the economic burden can be substantial for women, said Ayman Al-Hendy, MD, professor of obstetrics and gynecology at the University of Chicago Medicine.
Read More
What We’re Reading: Biden to Extend PHE Once More; High Court Rejects Pharma Suits; 988 Calls Soar
January 10th 2023President Joe Biden expected to renew COVID-19 public health emergency (PHE) one more time; Bristol Myers Squibb and Pfizer are denied by the Supreme Court; funding for the 988 mental health helpline expands inclusivity efforts.
Read More
HHS updated guidance for states using Medicaid managed care to manage nonmedical needs; anxieties surrounding new variants rise amidst underreported COVID-19 cases in China, which defended its counts; public health campaigns try new strategies to increase trust and promote immunizations.
Read More
Dual-regimen abortion pills authorized for pharmacy sale by FDA; health professionals turn a critical eye to US concerns about COVID-19 in China while domestic cases rise here as vaccination rates drop; drug manufacturers are collectively raising prices early this month on medications from autoimmune treatments to shingles vaccines to cancer treatments.
Read More
The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
Read More
Top 5 Most-Viewed Reimbursement Content in 2022
December 30th 2022The top 5 pieces of content published on AJMC.com relating to reimbursement issues included 2 on the significance of a California law giving Medicare beneficiaries access to expert oncology care; other articles looked at the work involved in value-based care models and CMS news.
Read More